Medscape April 2, 2025
A generative artificial intelligence (Gen-AI)–powered therapy chatbot known as Therabot was associated with significant reductions in several mental health conditions, including major depressive disorder (MDD).
Developed by members of the investigative team, Therabot is a mobile app that allows users to interact with a digital presence they understand is not a real person. Using user prompts and conversation history, the chatbot delivers tailored dialogue, including empathetic responses and targeted questions.
In a randomized control trial (RCT) of more than 200 US participants, those who received the chatbot intervention for 4 weeks had significantly greater symptom reductions in MDD, generalized anxiety disorder (GAD), and feeding and eating disorders (EDs) than their peers who did not receive access to the app (waitlist...
Today's Sponsors
Today's Sponsor